ACTRN12621000067875尚未招募1 期
A Phase I Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Aerosolised Ethanol for COVID-19 disease in Healthy Adult Volunteers and Adults with Underlying Lung Disease
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Able to understand, give consent, and comply with all scheduled study visits, procedures and restrictions.
- •2. Group 1. Healthy adult volunteers (6 participants) as judged by the investigator based on medical history, physical examination, vital signs, laboratory tests and ECG; and is a non-smoker defined as not having smoked (inhalation of tobacco/nicotine or drugs of abuse) for four weeks prior to the study.
- •3. Group 2 participants with underlying lung disease as specified - smokers (4 participants see below), asthmatics (4 participants) and patients with cystic fibrosis (4 participants). These patients should have no other associated co-morbidities such as cardiovascular, renal or liver - either diagnosed or suspected through the tests listed to be performed at screening. Their underlying condition must be stable as defined by no exacerbations or significant changes in their underlying condition or treatment for the past four weeks. The participant will be advised to have the permission of their treating physician to participate in this study.
- •4. Group 2 participants in the smokers group must be regular smokers as defined by the
- •minimum pack year history (1 pack/week for 6 months) and must be able to withhold
- •smoking for the duration of the testing as they will be in a non-smoking environment and will not be able to leave the premises during testing. These patients should also have no other associated co-morbidities such as cardiovascular, renal or liver - either diagnosed or suspected through the tests performed at screening.
排除标准
- •1. Under the age of 18 years. No upper age limits.
- •2. The COVID-19 serology or swab test performed at screening is positive.
- •3. Participants with a known diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or who, at screening, have an FEV1/FVC reading on spirometry of less than 70% predicted which is indicative of COPD.
- •4. Participants in Group 2 who at screening have an FEV1 reading on spirometry of less than 40% predicted.
- •5. Positive hepatitis or HIV serology testing performed at screening.
- •6. Participant is pregnant or breast-feeding.
- •7. Participants known to be allergic or have reacted to alcohol in the past
- •8. Participants unable to be exposed to alcohol for any reason including religious or cultural reasons
- •9. In the opinion of the Investigator, the participant is unable to comply with the procedures required for the testing.
- •10. Previous history of alcohol dependence or abuse, defined as greater than 21 units per week for males and greater than 14 units per week for females. Where 1 unit equals 360 mL of beer, 150 mL wine or 45 mL of spirits.
- •11. No specific medications are to be avoided, although if in the opinion of the medical staff that a new medication reported prior to starting the study has the potential for an interaction with ethanol, the participant will be precluded from participating while on that medication.
研究者
相似试验
已完成
不适用
A Phase I Study to Assess the Safety, Tolerability and Potential Therapeutic Dose of OMT-110 in Patients with metastatic colorectal cancerDiseases of the digestive systemKCT0005336MetiMedi Pharmaceuticals12
已完成
不适用
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LAM-001 in Patients with LymphangioleiomyomatosisNL-OMON48177AI Therapeutics6
已完成
1 期
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell MalignanciesPart1: Advanced B-cell MalignanciesPart2: r/rCLL and r/rMCLPart3: Untreated CJPRN-jRCT2080223591AstraZeneca34
已完成
不适用
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients with Advanced Cancer.advanced cancer10027656NL-OMON44662Sanofi-aventis57
已完成
不适用
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants with Mild to Moderate Alzheimer*s Disease.NL-OMON50153Alector Inc.10